This study is currently not recruiting participants.

A Phase II Evaluation of Pazopanib in the Treatment of Recurrent or Persistent Carcinoma of the Uterus

Study on Investigational Medication for Uterine Carcinosarcoma

Not Recruiting
18 years - 100 years
All
Phase N/A

Brief description of study.

The purpose of this study is to see if the drug pazopanib will cause uterine cancer (called carcinosarcoma) to shrink and to find out what side effects are caused by treatment with this drug.

Detailed description of study

The purpose of this study is to see if the drug pazopanib will cause uterine cancer (called carcinosarcoma) to shrink and to find out what side effects are caused by treatment with this drug.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Uterine Cancer
  • Age: 18 years - 100 years
  • Gender: All

The purpose of this study is to investigate if an investigational medication can cause uterine cancer, specifically carcinosarcoma, to decrease in size. Carcinosarcoma is a type of cancer that occurs in the uterus and is composed of two types of tissues, carcinoma and sarcoma.

Participants in the study will receive the investigational medication to determine its effects on the cancer and to monitor any side effects experienced during the treatment.

  • Who can participate: Participants should be within a specific age range and have a diagnosis of uterine carcinosarcoma. Further criteria may apply.
  • Study details: Participants will take the investigational medication to assess its impact on uterine carcinosarcoma and observe any side effects. A placebo will not be used in this study.
Updated on 19 Feb 2024. Study ID: 1105005439

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team